Securities code: 688488 securities abbreviation: Jiangsu Aidea Pharmaceutical Co.Ltd(688488) Announcement No.: 2022-010 Jiangsu Aidea Pharmaceutical Co.Ltd(688488)
Announcement of resolutions of the 17th meeting of the first board of supervisors
The board of supervisors and all supervisors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal liabilities for the authenticity, accuracy and integrity of its contents according to law.
1、 Meetings of the board of supervisors
The notice of the 17th meeting of the first board of supervisors (hereinafter referred to as “the company”) was delivered to all supervisors on January 14, 2022. The meeting was held on January 19, 2022 in the company’s conference room by on-site combined with communication voting. The meeting was convened and presided over by Mr. Yu Heng, chairman of the board of supervisors of the company. There were 3 supervisors and 3 supervisors. The convening and convening procedures of this meeting comply with the company law of the people’s Republic of China, the articles of association and other relevant provisions, and the resolutions formed at the meeting are legal and effective.
2、 Deliberation at the meeting of the board of supervisors
The attending supervisors deliberated on the following proposals and voted on the following matters:
(I) deliberated and passed the proposal on the company’s restricted stock incentive plan in 2022 (Draft) and its summary
The board of supervisors of the company believes that the contents of the company’s restricted stock incentive plan (Draft) in 2022 and its abstract comply with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the measures for the administration of equity incentive of listed companies and the Listing Rules of shares on the science and Innovation Board of Shanghai Stock Exchange The provisions of relevant laws, regulations and normative documents such as self regulatory guidelines for listed companies on the science and Innovation Board No. 4 – disclosure of equity incentive information. The implementation of this incentive plan will be conducive to the sustainable development of the company, and there will be no damage to the interests of the company and all shareholders.
For details, please refer to the website of Shanghai Stock Exchange (www.sse. Com. CN.) disclosed by the company on the same day The Jiangsu Aidea Pharmaceutical Co.Ltd(688488) 2022 restricted stock incentive plan (Draft) and the summary announcement of Jiangsu Aidea Pharmaceutical Co.Ltd(688488) 2022 restricted stock incentive plan (Draft) (Announcement No.: 2022-004).
Voting results: 3 in favor, 0 against and 0 abstention.
This proposal needs to be submitted to the general meeting of shareholders for deliberation.
(II) deliberated and passed the proposal on the company’s measures for the assessment and management of the implementation of the restricted stock incentive plan in 2022
The board of supervisors of the company believes that the management measures for the implementation and assessment of the restricted stock incentive plan in 2022 complies with the provisions of relevant laws and regulations and the actual situation of the company, can ensure the smooth implementation of the restricted stock incentive plan in 2022, further improve the corporate governance structure and form a good and balanced value distribution system, Establish a benefit sharing and restraint mechanism between shareholders and employees of the company.
For details, please refer to the website of Shanghai Stock Exchange (www.sse. Com. CN.) disclosed by the company on the same day Administrative measures for the implementation and assessment of Jiangsu Aidea Pharmaceutical Co.Ltd(688488) 2022 restricted stock incentive plan.
Voting results: 3 in favor, 0 against and 0 abstention.
This proposal needs to be submitted to the general meeting of shareholders for deliberation.
(III) the proposal on verifying the company’s list of incentive objects granted for the first time under the restricted stock incentive plan in 2022 was deliberated and adopted
After the preliminary verification of the list of incentive objects granted for the first time in the company’s restricted stock incentive plan in 2022, the board of supervisors believes that the personnel included in the list of incentive objects granted for the first time in the company’s restricted stock incentive plan have the qualifications specified in the company law of the people’s Republic of China and other laws, regulations and normative documents and the articles of association, There is no situation that the stock exchange has identified it as an inappropriate candidate within the last 12 months; There is no case that the CSRC and its dispatched offices have identified it as an inappropriate candidate within the last 12 months; There are no cases in which the CSRC and its dispatched offices have imposed administrative penalties or taken market entry prohibition measures for major violations of laws and regulations in the last 12 months; There are no circumstances under which the company law of the people’s Republic of China stipulates that he shall not serve as a director or senior manager of the company; There are no circumstances in which it is not allowed to participate in the equity incentive of listed companies according to laws and regulations, meet the incentive object conditions specified in the administrative measures for equity incentive of listed companies and the Listing Rules of science and Innovation Board of Shanghai Stock Exchange, and meet the incentive object scope specified in the company’s restricted stock incentive plan (Draft) in 2022 and its summary, The subject qualification as the incentive object of the company’s restricted stock incentive plan is legal and effective.
The company will publicize the names and positions of incentive objects within the company through the company’s website or other channels before the general meeting of shareholders, and the publicity period shall not be less than 10 days. The board of supervisors will disclose the audit opinions on the list of incentive objects and the explanation of their publicity five days before the shareholders’ meeting considers the equity incentive plan.
Voting results: 3 in favor, 0 against and 0 abstention.
(IV) the proposal on changing some special accounts for raised funds and adding new special accounts for raised funds was reviewed and approved
The board of supervisors of the company believes that the change of some special accounts for raised funds and the new special accounts for raised funds meet the actual situation and operation and management needs of the company, which is conducive to strengthening the management of raised funds, Comply with the relevant provisions of the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies, the Listing Rules of the science and Innovation Board of Shanghai Stock Exchange, the measures for the administration of raised funds by listed companies of Shanghai Stock Exchange and the company’s measures for the administration of raised funds. The review procedures for the change of the special account for raised funds and the new special account for raised funds comply with the provisions of laws, administrative regulations, departmental rules and other normative documents, and there is no situation of changing the investment direction of raised funds or damaging the interests of shareholders in a disguised manner.
For details, please refer to the website of Shanghai Stock Exchange (www.sse. Com. CN.) disclosed by the company on the same day Announcement on Jiangsu Aidea Pharmaceutical Co.Ltd(688488) changing some special accounts for raised funds and adding special accounts for raised funds (Announcement No.: 2022-005).
Voting results: 3 in favor, 0 against and 0 abstention.
(V) deliberated and passed the proposal on the estimation of the company’s daily connected transaction quota in 2022
The board of supervisors of the company believes that the estimated amount of daily connected transactions of the company in 2022 is carried out in accordance with the principles of fairness, impartiality and openness, and will not damage the interests of the company and all shareholders. The deliberation and voting procedures comply with the company law, the securities law and other laws and regulations as well as the relevant provisions of the articles of association, Agree to the proposal of the company’s daily connected transaction quota forecast in 2022.
For details, please refer to the website of Shanghai Stock Exchange (www.sse. Com. CN.) disclosed by the company on the same day Announcement Jiangsu Aidea Pharmaceutical Co.Ltd(688488) on the forecast of the company’s daily connected transaction quota in 2022 (Announcement No.: 2022-006).
Voting results: 3 in favor, 0 against and 0 abstention.
It is hereby announced.
Jiangsu Aidea Pharmaceutical Co.Ltd(688488) board of supervisors January 20, 2022
